Inhibition of interleukin-6 (IL-6) holds significant promise as a therapeutic approach for triple negative breast cancer (TNBC). We previously reported that phenylmethimazole (C10) reduces IL-6 expression in several cancer cell lines. We have identified a more potent derivative of C10 termed COB-141. In the present work, we tested the hypothesis that C10 and COB-141 inhibit TNBC cell expressed IL-6 and investigated the potential for classical IL-6 pathway induced signaling within TNBC cells. A panel of TNBC cell lines (MDA-MB-231, Hs578T, MDA-MB-468) was used. Enzyme linked immunosorbent assays (ELISA) revealed that C10 and COB-141 inhibit MDA-MB-231 cell IL-6 secretion, with COB-141 being~6.5 times more potent than C10. Therefore, the remainder of the study focused on COB-141 which inhibited IL-6 secretion, and was found, via quantitative real time polymerase chain reaction (QRT-PCR), to inhibit IL-6 mRNA in the TNBC panel. COB-141 had little, if any, effect on metabolic activity indicating that the IL-6 inhibition is not via a toxic effect. Flow cytometric analysis and QRT-PCR revealed that the TNBC cell lines do not express the IL-6 receptor (IL-6Rα). Trans-AM assays suggested that COB-141 exerts its inhibitory effect, at least in part, by reducing NF-κB (p65/p50) DNA binding. In summary, COB-141 is a potent inhibitor of TNBC cell expressed IL-6 and the inhibition does not appear to be due to non-specific toxicity. The TNBC cell lines do not have an intact classical IL-6 signaling pathway. COB-141's inhibitory effect may be due, at least in part, to reducing NF-κB (p65/p50) DNA binding.
Introduction
Approximately 10-20% of women diagnosed with breast cancer have triple negative breast cancer (TNBC) (Lehmann et al., 2011) , which is particularly aggressive and difficult to treat (Hudis and Gianni, 2011) . Several lines of evidence suggest that the pleiotropic inflammatory cytokine interleukin-6 (IL-6), which can be produced by many cell types, including tumor cells, plays a significant role in TNBC [e.g. (Barbie et al., 2014; Hartman et al., 2013; Knupfer and Preiss, 2007; Zhang and Adachi, 1999) ]. Thus, inhibition of IL-6 activity has emerged as an important therapeutic target for TNBC [e.g. (Clinical Trialsgov Identifier:NCT, 0204, 1429 ].
IL-6 inhibition could be achieved by disrupting the production of IL-6 and/or disrupting IL-6 signaling. In regard to the latter approach, IL-6 signal transduction is initiated when IL-6 binds to either the membrane-bound (classical pathway) or soluble (trans pathway) form of the IL-6 receptor (IL-6Rα) (Goldberg and Schwertfeger, 2010) . The resulting complex associates with glycoprotein 130 (gp130), which homodimerizes, triggering Janus kinase (JAK) activation that leads to tyrosine phosphorylation of signal transducers and activators of transcription (STAT) proteins (Wolf et al., 2014) . IL-6 can also signal through the mitogen activated protein kinase (MAPK) as well as the phosphatidyl-inositol-3-kinase (PI3K) cascades (Eulenfeld et al., 2012) . Several strategies for disrupting IL-6 signaling are being pursued. Ruxolitinib, a selective JAK1/2 inhibitor, and related compounds (e.g.
INCB24360)
, are being investigated for use in solid tumors including TNBC (Clinical Trialsgov Identifier:NCT, 0204, 1429 . While this approach holds promise, the development of the JAK1/2 inhibitor AZD1480 was recently discontinued due to dose-limiting toxicities and lack of clinical activity observed in targeting solid tumors (Plimack et al., 2013) . Biologics targeting IL-6Rα or IL-6 have also been investigated for use as cancer therapeutics (Rossi et al., 2010; Zheng et al., 2014) . However, a clinical study investigating CNTO328, a mAb to IL-6, found an increase in IL-6 with CNTO328 treatment (Dorff et al., 2010) .
Thus, there is significant interest in targeting IL-6 and developing complementary approaches, such as inhibiting the production of IL-6, is clearly warranted. Previously we found that phenylmethimazole [C10 (Fig. 1) ; (4-phenyl-3-methyl-1, 3 imidazole-2-thione)], inhibits estrogen receptor α+ breast, melanoma and pancreatic cancer cell IL-6 expression in vitro (Schwartz et al., 2009 (Schwartz et al., , 2016 and tumor growth in vivo (Schwartz et al., 2009) . We have identified a potentially more potent derivative of C10 [COB-141 ( Fig. 1) ] through a general compound screening program. Specifically, the heterocyclic ring of C10 contains a slightly acidic unsubstituted NH in the 3 positon. We altered C10 by extending the N-1 alkyl chain from a methyl to an npropyl which may facilitate cell membrane transit, and changing the N-3 to an S providing the thiazole derivative (Fig. 1) . Thiazoles are important anti-inflammatory agents (Pattan et al., 2009; Siddiqui et al., 2009 ) and previous studies have suggested that thiazoles may exhibit higher efficacy than imidazoles in certain settings (Unangst et al., 1994) .
Thus, based on our previous findings, and the importance of IL-6 in TNBC, we explored the hypothesis that C10 and COB-141 potently reduce TNBC cell expression of IL-6.
Materials and methods

Cell culture and treatment
The TNBC cell lines MDA-MB-231 [American Type Culture Collection, Manassas, VA (ATCC); HTB-26], MDA-MB-468 (ATCC HTB-132), and the ERα+ breast cancer cell line MCF7 (ATCC HTB-22), were cultured in Dulbecco's Modified Eagle Medium (DMEM) with high glucose (Thermo Scientific; Waltham, MA), 10% heat inactivated fetal bovine serum (FBS) (Lonza; Walkersville, MD), and 1% penicillin/streptomyocin (Lonza). The Hs578T cell line (ATCC HTB-126) was cultured in DMEM with 0.01 mg/ ml bovine insulin (Sigma-Aldrich; St. Louis, MO), 10% heat inactivated FBS, and 1% penicillin/streptomycin. Undifferentiated THP-1 cells (ATCC TIB-202) were cultured in medium RPMI-1640 (ATCC) supplemented with 10% non-heat inactivated FBS and 0.05 mM β-mercaptoethanol (Gibco, Grand Island, NY). For compound treatment, cells were treated with fresh media containing C10, COB-141 or 0.25% dimethyl sulfoxide (DMSOsolvent control) (Sigma). For studies lasting 48 h, culture media containing the appropriate treatment was replaced at 24 h.
Quantitative real-time polymerase chain reaction (QRT-PCR)
Post-treatment, cells were lysed directly on the growth surface. Lysates were homogenized using QIAshredder microcentrifuge spincolumn homogenizers and were purified using the RNeasy Mini Kit, both purchased from Qiagen (Valencia, CA) (Schwartz et al., 2009) . Genomic DNA was eliminated using the RNase-free DNase Set (Qiagen) (Schwartz et al., 2009) . Purified mRNA samples were quantified using the Nanodrop 2000 Micro-volume UV-vis Spectrophotometer (Thermo). cDNA was subsequently synthesized from 1000 ng of each sample with the High Capacity cDNA Reverse Transcription Kit purchased from Applied Biosystems (Carlsbad, CA). Real-time PCR was performed using Taqman® Gene Expression Assays, Taqman® Gene Expression Master Mix, and the Step-One-Plus™ Real-Time PCR System (Applied Biosystems). HPRT-1 was used as the endogenous control primer alongside target primers in a multiplex format. Results were calculated using the ΔΔC T method, and represented as fold expression relative to 0.25% DMSO or THP-1 control samples.
Enzyme linked immunosorbent assays (ELISA) and MTS assays
Post-treatment, the supernatants from cells were harvested and centrifuged to remove cells and cellular debris, and stored at −20°C until used in the ELISA. The BD OptEIA Human IL-6 and IL-8 ELISA Set and Reagent set B (BD Biosciences) were conducted according to manufacturer specifications. Results are represented as averages of percent inhibition of IL-6 or IL-8 relative to solvent control (0.25% DMSO). The CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Kit (Promega; Madison, WI) was used to determine metabolic activity according to the manufacturer's protocol and as previously described (Alapati et al., 2015) . OD 490 nm was determined using a Synergy HT Multi-Mode Microplate Reader (BioTek, Winooski, VT). Results are given as a percent (%) MTS signal relative to the signal observed with 0.25% DMSO. The MTS signal from wells containing media alone was subtracted from all readings prior to determining the %MTS signal.
Flow cytometry analysis (FCA)
FCA was performed as previously described (Burdick et al., 2006 2.5. Detection of NF-кB (p65/p50) DNA-binding activity NF-кB (p65/p50) DNA binding activity in nuclear protein extracts of the TNBC cells was quantified with an ELISA-based assay. Nuclear proteins were extracted using NE-PER nuclear and cytoplasmic extraction kit (Thermo) then quantified using the micro BCA protein assay kit (Thermo) and Nanodrop 2000 Micro-volume UV-Vis Spectrophotometer (Thermo). Trans-AM NF-кB (p65/p50) transcription factor ELISA assays (Active Motif; Carlsbad, CA) were performed on 10 µg of extracted nuclear proteins according to manufacturer's protocol and analyzed using a Synergy HT Multi-Mode Microplate Reader (BioTek). 
Results
A panel of TNBC cell lines express significant levels of interleukin 6 (IL-6)
Earlier work has shown that TNBC cell lines constitutively express IL-6 [e.g. for MDA-MB-231 cell line (Armenante et al., 1999) ]. Thus, we sought to determine if the TNBC cell lines MDA-MB-231, MDA-MB-468 and Hs578T cultured in our laboratory secrete IL-6. As a comparison, we determined the level of IL-6 secretion by the ER+ breast cancer cell line MCF7. As shown in Fig. 2 , the level of IL-6 protein secreted by the TNBC cell lines is significantly higher than the MCF7 cell line with the MDA-MB-231 and Hs578T cell lines secreting the highest levels and the MDA-MB-468 the lowest. Strikingly, the levels of IL-6 protein secreted by MDA-MB-231 and Hs578T cells is > 250 fold higher than that expressed by MCF7 cells and even the MDA-MB-468 cells secrete nearly 10 fold higher levels of IL-6 compared to the MCF7 cells (Fig. 2) .
C10 and COB-141 inhibit IL-6 expression by MDA-MB-231 cells
Our first step was to determine if C10 would inhibit IL-6 expression in MDA-MB-231 cells. In addition, we previously created a derivative of C10 by substituting the imidazolidinone ring of C10 for a thiazolidinone ring and extending the alkyl chain on N-1 from a methyl to a propyl affording COB-141 (Fig. 1) . We have found that COB-141 has greater potency than C10 in several in vitro assays (not shown). Thus, we also investigated the effect of COB-141 on IL-6 expression by MDA-MD-231 cells. MDA-MB-231 were treated with varying concentrations of C10 (20-500 µM) or COB-141 (6.25-100 µM) for 24 h and, subsequently, the level of IL-6 present in the supernatant determined via ELISA. The lower concentrations utilized for COB-141, relative to C10, was due to the greater potency of COB-141.
Both C10 and COB-141 significantly inhibited IL-6 secretion ( Fig. 3) . At concentrations > 125 μM, as the concentration of C10 increased, the level of IL-6 secretion decreased (Fig. 3A) . As the concentration of COB-141 increased, the level of IL-6 secretion decreased (Fig. 3B) . To compare the potencies of C10 and COB-141, we estimated IC 50 for each compound, i.e. the concentration needed to inhibit 50% of basal IL-6 secretion. A best fit regression of the data was performed and the estimated IC 50 determined from the resulting curve. The IC 50 for C10 was estimated to be 230 μM and the IC 50 for COB-141 was estimated to be 35 μM. Since COB-141 is more potent than C10, we focused the remainder of the study on COB-141. We sought to determine if the inhibition of IL-6 was occurring at the mRNA level. MDA-MB-231 cells were treated with COB-141 at concentrations ranging from 6.25 to 100 μM for 24 h and, subsequently, the IL-6 mRNA was quantified using QRT-PCR. IL-6 mRNA decreased as the concentration of COB-141 increased (Fig. 4) . The IC 50 for COB-141 inhibition of IL-6 mRNA was estimated to be 61 µM. 
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To determine if the results with the MDA-MB-231 cell line are generalizable to other TNBC cell lines, we investigated the effect of COB-141 on the TNBC cell lines, Hs578T and MDA-MB-468. As described in the above sections for the MDA-MB-231 cell line, the effect of COB-141 on IL-6 secretion and mRNA expression was determined via ELISA and QRT-PCR. COB-141 significantly reduced IL-6 secretion (Fig. 5A,B ) and mRNA expression (Fig. 5C,D) in both the Hs578T (Fig. 5A,C) and MDA-MB-468 cell lines (Fig. 5B,D) . The IC 50 for IL-6 secretion was estimated to be 70 μM for the Hs578T and 13 μM for the MDA-MB-468 cells. The IC 50 for IL-6 mRNA was estimated to be 16 μM for the Hs578T and 50 μM for the MDA-MB-468 cells. Thus, COB-141 inhibition of basal IL-6 expression was generalizable to other TNBC cell lines.
3.4. COB-141 exhibits a relatively limited, if any, effect on the metabolic activity of the panel of TNBC cell lines at the concentrations tested for IL-6 inhibition Inhibition of IL-6 expression could be due to a "non-specific" toxic effect on the TNBC cells. To gain insight into this possibility, we sought to determine if COB-141 treatment has a significant effect on the TNBC cell lines' viability as measured by a metabolic (MTS) assay. 48 h treatment with COB-141 had a quite limited effect on the metabolic activity of the TNBC cell lines (Fig. 6 ) that did not parallel the rather dramatic inhibitory effect of COB-141 on IL-6 expression (Figs. 3B,4 and 5). For example, at 50 μM, there is little effect on metabolic activity (Fig. 6) despite the fact that this concentration of COB-141 yields a significant reduction in IL-6 secretion and mRNA expression (Figs. 3B,4 and 5). There might be a slight effect of COB-141 on the metabolic activity of the Hs578T cell line (Fig. 6 ) at moderate concentrations, but even in this case, the effect is not as dramatic as the effect on IL-6 (Fig. 5A,C) . Note that we chose to use 48 h for this assay, as opposed to 24 h used in the IL-6 inhibition analysis, reasoning that toxic effects might not manifest themselves until a later time point. Thus, it appears that the inhibitory effect of COB-141 on IL-6 expression is not due to "non-specific" cell toxicity.
The panel of TNBC cells lack expression of IL-6 receptor α (IL-6Rα) but do express gp130
A reduction in IL-6 expression could exert a therapeutic result via a direct effect on the tumor cells themselves or by acting on the nontumor cells present in the tumor microenvironment. To investigate the former possibility, we sought to determine if the panel of TNBC cell lines expresses the IL-6 signaling molecules (receptors) IL-6Rα and gp130. The panel of TNBC cell lines expressed little, if any, IL-6Rα mRNA compared to that expressed by THP-1 cells [positive control (Vermes et al., 2002) ] (Fig. 7) . In addition, IL-6Rα protein was not detected on the panel of TNBC cell lines (Fig. 7) via flow cytometric analysis (FCA). In contrast, IL-6Rα protein was detected on THP-1 cells consistent with previous reports (Vermes et al., 2002) . These results (Fig. 7) provide compelling evidence that the panel of TNBC cell lines do not express IL-6Rα. Interestingly, FCA (Fig. 7) and QRT-PCR ( Table 1 ) did reveal that all three cell lines express gp130. Hs578T and MDA-MB-468 cells were treated with a range of COB-141 concentrations to determine the dose dependent effect on IL-6 protein secretion (A and B) and mRNA expression (C and D) which allowed estimation of an IC 50 value for each. For each study, the dose response was determined in three separate experiments. The results at each dose were averaged for the three experiments. These averages (+/-the S.E.M.) were plotted vs the concentration of COB-141 to arrive at the figures shown. A best fit regression of the data was performed and the IC 50 determined from the resulting curves.
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We next initiated an investigation into the possible mechanism(s) by which COB-141 inhibits IL-6 expression. For this we focused on the transcription factor NF-κB, specifically the canonical p65/p50 pathway, since it plays a key role in inflammatory cytokine regulation, including IL-6 (Lawrence, 2009; Libermann and Baltimore, 1990) , and has been implicated in IL-6 expression by TNBC cells (Hartman et al., 2013) . p65/p50 is normally sequestered in the cytoplasm under the regulation of IκB. Upon activation, IκB is phosphorylated and degraded (Lawrence, 2009 ). The degradation of IκB frees p65/p50 to translocate to the nucleus where it can bind to its DNA binding motifs and initiate transcription (Lawrence, 2009) . Although the mobilization of p65/p50 to the nucleus is typically in the context of activation of the cells with a stimulus, we reasoned that probing p65/p50 was a rational place to start our investigation into mechanism.
Thus, we treated the panel of TNBC cells with COB-141 or DMSO (carrier control), subsequently isolated the nuclear proteins from the cells and used a Trans-AM assay to measure p65/p50 binding to its DNA binding motifs. As shown in Fig. 8 , COB-141 did appear to reduce the level of p65/p50 DNA binding in all three TNBC cells lines with the size of the effect ranging from distinct (~30% reduction) to modest (~10% reduction). Therefore, it appears that COB-141 may inhibit IL-6 expression by the panel of TNBC cells, at least in part, by reducing p65/p50 DNA binding.
COB-141 inhibits IL-8 expression in the Hs578T and MDA-MB-468 but not the MDA-MB-231 TNBC cell lines
Previous work has linked TNBC IL-8 and IL-6 expression mechanistically through NF-κB (Hartman et al., 2013) . Thus, we sought to investigate COB-141's effect on IL-8. As shown in Fig. 9A and B, COB-141 did have a significant effect on IL-8 protein secretion by the Hs578T (IC 50 14 μM) and MDA-MB-468 (IC 50 35 μM) cell lines. In striking contrast to these results, COB-141 did not inhibit MDA-MB-231 cell secretion of IL-8 (Fig. 9C) . Thus, the results obtained for IL-6 cannot necessarily be extrapolated to predict what effect COB-141 will have on the secretion of the mechanistically related cytokine IL-8. The discordant results between the cell lines for IL-8 do, however, underscore the significance of the IL-6 findings presented in Figs. 3-5 in that a similar result was observed for three different TNBC cell lines.
Discussion
Our team has worked extensively with a derivative of MMI termed C10 [e.g. (Alapati et al., 2015; Dagia et al., 2004; Harii et al., 2005; McCall et al., 2010; Schwartz et al., 2009) ]. C10 differs from MMI by the presence of a hydrophobic phenyl group (Fig. 1) , which presumably facilitates transport into the cell thereby increasing activity. We have recently provided in vitro evidence that C10 exhibits greater activity than MMI (Alapati et al., 2015) . Directly related to the present work, research pioneered by the McCall lab revealed that C10 reduces IL-6 expression by several cancer cell lines (McCall et al., 2007; Schwartz et al., 2009) including, most recently, the ERα+ breast cancer cell line MCF7 (Schwartz, in press et al., ) , and inhibits tumor growth in murine models (Schwartz et al., 2009 ). In addition, our compound screening program identified a C10 derivative, COB-141, that appears to be more potent than C10. Both of these compounds were tested in this study.
Our initial results revealed that both C10 and COB-141 inhibit basal IL-6 expression by MDA-MB-231 cells (Fig. 3) and that COB-141 is 6.5 times more potent than C10. Thus, we focused the remainder of our study on COB-141. We found that COB-141 is a potent inhibitor of IL-6 secretion by a panel of TNBC cell lines and COB-141 acts at the mRNA level (Figs. 4 and 5) . The inhibition of IL-6 does not appear to be due to a non-specific toxic effect as an MTS assay revealed little, if any, decrease in metabolic activity upon treatment with COB-141 (Fig. 6) . In addition, the data presented in Fig. 8 , indicate that COB-141 exerts its inhibitory effect, at least in part, by decreasing the level of nuclear NF-κB (p65/p50) DNA binding; a finding that is congruent with COB-141 inhibiting IL-6 transcription (Figs. 4 and 5) . The regulation of NF-κB is complex [e.g. (Hartman et al., 2013; Lawrence, 2009)] and future studies will be needed to further elucidate the details by which COB-141 might inhibit p65/p50 DNA binding activity. Interestingly, the inhibition of IL-6 was not generalizable to another closely related cytokine IL-8 (Hartman et al., 2013) . Specifically, while we found that COB-141 inhibited IL-8 secretion by Hs578T and MDA-MB-468 cells, it did not inhibit, and may have actually increased, IL-8 secretion by MDA-MB-231 cells (Fig. 9) .
The results for IL-6 (and to a certain extent IL-8) reveal that COB-141 defines a chemical design space which contains potential therapeutics for TNBC. To exert an inhibitory effect on tumor growth and progression, it is reasonable to postulate that a reduction in IL-6 would achieve a therapeutic effect by directly affecting the tumor cells and/or diminishing the growth promoting characteristics of the microenvironment. Our data suggest that inhibition of IL-6 may not have a direct effect on tumor cells Fig. 6 . At the concentrations tested for IL-6 inhibition, COB-141 has a limited effect on the metabolic activity of the panel of TNBC cell lines. MDA-MB-231 (A), Hs578T (B) and MDA-MB-468 (C) cells were treated with various concentrations of COB-141 for 48 h. Subsequently, an MTS assay was used to determine the effect of the compound on metabolic activity. For each study, the dose response was determined in three separate experiments. The results at each dose were averaged for the three experiments. These averages (+/-the S.E.M.) were plotted vs the concentration of COB-141 to arrive at the figures shown.
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European Journal of Pharmacology 803 (2017) 130-137 themselves via the classical IL-6 signaling pathway, at least in some cases. First, we observed limited, if any, effect on TNBC cell metabolic activity at COB-141 concentrations that resulted in significant inhibition of 4, 5) . In this regard, it is important to note that treatment with COB-141 did not yield complete inhibition of IL-6 raising the possibility that a compound that reduced IL-6 to nil might achieve an effect on metabolic activity. That said, the second piece of evidence supporting no direct effect on the tumor cells via the classical IL-6 pathway is that the panel of TNBC cells used in this study did not appear to have IL-6Rα as assessed by both flow cytometric analysis and QRT-PCR (Fig. 7) . There is the possibility that IL-6 signaling could occur through the trans pathway since these cells do express gp130 (Fig. 7 and Table 1 ). In the case of trans-signaling it would appear that the sIL-6Rα would need to be provided by another cell within the tumor since the panel of TNBC cell lines tested did not express IL-6Rα mRNA (Fig. 7) . If it is true that a particular TNBC tumor cell's growth is not dependent on a direct effect of IL-6 on the tumor cells themselves via either the classical or trans pathways, an IL-6 inhibitor could still decrease tumor growth in vivo through actions on the tumor microenvironment. Indeed, inhibition of IL-6 signaling has been shown to reduce tumor growth in vivo, even under the circumstance where there is no direct effect on tumor cell growth and viability in vitro [e.g. (Chang et al., 2013) ]. Thus, continuing a concerted effort to identify, characterize and develop potent IL-6 inhibitors is clearly warranted. While our study has focused on IL-6 expression, it is possible that COB-141 has other effects as well. One intriguing possibility would be COB-141 altering the "stemness" of the cell population. For breast cancer, cancer stem cell markers (CSCs) include the canonical CSC markers CD24, CD44, and ALDH1 (Akbari-Birgani et al., 2016; CieslarPobuda et al., 2015; Farahani et al., 2014; Sansone et al., 2016) . Thus, in a preliminary study we utilized flow cytometric analysis with immunolabeling and an Aldefuor assay to investigate the effects of COB-141 on the expression of CD24/CD44 and ALDH1 activity, respectively, in the panel of TNBC cell lines. COB-141 did not appear to change the expression of these stem markers in any of the TNBC cell lines tested. Given the complexity of this issue [e.g. there are other markers of stemness and the type of cell culture (2D vs 3D) can influence stemness], there is still much that could be explored regarding the effect of COB-141 on stemness. Other possible effects of COB-141 include altering key regulators of the cell cycle [e.g. PFKFB3 (Cieslar-Pobuda et al., 2015) ] that might manifest at time points after those investigated in the MTS study presented here (Fig. 6) . (Vermes et al., 2002) , and that the mAb for IL-6Rα works as expected. All three TNBC cell lines were positive for gp130 (solid black line) consistent with the results from the QRT-PCR (Table 1) . Results representative of three separate experiments.
European Journal of Pharmacology 803 (2017) 130-137 In conclusion, we found that (i) C10 and COB-141 inhibit IL-6 secretion by a TNBC cell line, (ii) COB-141 is significantly more potent than C10, (iii) COB-141 inhibits IL-6 expression in a panel of TNBC cell lines at both the protein and mRNA level, (iv) a panel of TNBC cell lines do not appear to have an intact classical IL-6 signaling pathway, and (v) COB-141 may exert its inhibitory effect, at least in part, by reducing NF-κB (p65/p50) DNA binding.
Conflict of interest
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